Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: antibody therapeutics - F-star Therapeutics

Next Previous
Drug Profile

Research programme: antibody therapeutics - F-star Therapeutics

Alternative Names: Fcab - F-star Therapeutics; Fcab antibody fragments - F-star Therapeutics; FS 101; FS 117; FS 17; FS 18; FS 20; FS 22; mAb²TM

Latest Information Update: 09 Mar 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator f-star
  • Developer F-star Therapeutics
  • Class Antineoplastics; Bispecific antibodies; Immunoconjugates
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Apoptosis stimulants; CD223 antigen inhibitors; Checkpoint kinase inhibitors; Epidermal growth factor inhibitors; ERBB 2 receptor agonists; Hepatocyte growth factor inhibitors; OX40 receptor agonists; Programmed cell death-1 ligand-1 inhibitors; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 09 Mar 2023 F-star Therapeutics has been acquired by invoX Pharma
  • 05 Jan 2022 Merck KGaA exercises fourth licensing option from option agreement with F-star Therapeutics for antibody therapeutics
  • 17 May 2021 Preclinical development is ongoing for Cancer in United Kingdom (F-star Therapeutics pipeline, May 2021)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top